07.01.2014
Vita 34 AG DE000A0BL849
DGAP-News: Vita 34 AG pursues growth strategy by taking over the majority stake in Stellacure
DGAP-News: Vita 34 AG / Key word(s): Investment
Vita 34 AG pursues growth strategy by taking over the majority stake
in Stellacure
07.01.2014 / 17:14
---------------------------------------------------------------------
Vita 34 AG pursues growth strategy by taking over the majority stake in
Stellacure
- Vita 34 takes over 75.24 percent of the shares in Stellacure GmbH
- Further strengthening of market leadership in German-speaking area by
take-over
- Future growth potential by establishing a second location in Germany
Leipzig, 7 January 2014 - Vita 34 AG (WKN A0BL84), trailblazer of the
umbilical cord blood storage in Europe and specialist in cryo-preservation,
takes over the majority stake in the umbilical cord blood bank Stellacure
GmbH. Through the application, which was already made, and the registration
in the Commercial Registry, which is expected in January 2014, Vita 34 will
take over 75.24 percent of the Stellacure shares. Both parties agreed not
to disclose the sales price. With this take-over, Vita 34 acquires an
established brand in the sector of Vita 34 private umbilical cord blood
banking and thus pursues the aspect of the growth strategy of further
expanding its own share in the German market.
The Stellacure GmbH was founded in Hamburg and Frankfurt in 2006 in
cooperation with the Blood Transfusion Service Baden-Württemberg-Hesse of
the German Red Cross (DRK). The operating activities of the Stellacure GmbH
include the extraction and processing of umbilical cord blood allowing for
the highest quality and safety standards. The cord blood is stored at
Stellacure's facility located in the building of the DRK Blood Transfusion
Service in Frankfurt on the Main. In addition to storages from Germany,
Stellacure furthermore works on the Italian and Spanish markets. The team
comprises specialists in transfusion and laboratory medicine as well as
experienced experts such as biologists, chemists, biotechnologists, and
engineers. Being the fourth eldest provider of umbilical cord blood storage
services in Germany, Stellacure produced a turnover of about 0.4 million
Euros in the fiscal year 2012.
Dr. André Gerth, CEO of Vita 34 AG: 'We are the market leader in the entire
German-speaking area with more than 98,000 stored stem cell preparations.
Our ambition is to strengthen this dominant position in a sustainable way.
We currently see a growing tendency to consolidation on the market of
private umbilical cord blood banking. This process provides us as the
market leader with considerable opportunities to gain additional market
shares. By taking over the majority of Stellacure, we now have a second
location in Germany besides Leipzig, based on which we are able to
establish a purposeful regional distribution and thus intensify the contact
with our relevant target group.'
Company profile
Vita 34 was founded in 1997 as the first private umbilical cord blood bank
in Europe and as a full-service provider takes care of the collection
logistics, processing, and storage of umbilical cord blood and umbilical
cord tissue. Its successful operation is based on an excellent position in
the technological segment of cryo-preservation. Cells and tissue are kept
alive at temperatures around minus 190 degrees Celsius and can be applied
in medical therapies if required. Parents of more than 98,000 children
already make use of this offer and have taken provisions for their children
by means of a stem cell depot at the company from Leipzig.
End of Corporate News
---------------------------------------------------------------------
07.01.2014 Dissemination of a Corporate News, transmitted by DGAP - a
company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: Vita 34 AG
Deutscher Platz 5a
04103 Leipzig
Germany
Phone: +49(0341)48792-40
Fax: +49(0341)48792-39
E-mail: [email protected]
Internet: www.vita34.de
ISIN: DE000A0BL849
WKN: A0BL84
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, Hamburg, München,
Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
247170 07.01.2014
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
Vita 34 AG ISIN: DE000A0BL849 können Sie bei EQS abrufen
Biotechnologie , A0BL84 , V3V , XETR:V3V